Lipo-C (No B12)
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Lipo-C (No B12) is not a single molecule but a considered assembly of four lipotropic agents – methionine, inositol, choline, and L-carnitine – each operating through a distinct but complementary pathway. Together they address the conditions under which the liver accumulates fat: insufficient methyl donors, impaired phospholipid synthesis, disrupted choline availability, and inadequate mitochondrial fatty acid transport. The formulation omits cyanocobalamin, making it suitable for individuals with B12 sensitivity or those managing intake through separate supplementation. What follows is a mechanism-level account of each constituent.
Methionine, inositol, and choline form the core lipotropic components in Lipo-C, each participating in pathways related to hepatic lipid handling and export. Choline contributes to phosphatidylcholine synthesis for VLDL assembly, while methionine supports methylation reactions tied to normal liver metabolism.
Inositol is included for its role in intracellular signaling and its historical use in lipotropic formulations intended to support fat mobilization. In this context, the combined formula is positioned as an adjunct to nutrition and exercise rather than a primary treatment for metabolic liver disease.
Administration patterns for Lipo-C typically involve intramuscular injection one to three times weekly in supervised practice. Course length commonly ranges from 4 to 12 weeks, depending on the formulation used and the clinical context.
Clinical use is best understood as supportive rather than definitive. These ingredients are generally used alongside calorie control, physical activity, and broader metabolic risk reduction strategies.
What we observe
What users noticed in fat burning markers
The following observations are drawn from studies of the individual constituents and, where available, combined lipotropic formulations. No controlled trial has evaluated this precise four-component injectable mixture in a large randomized cohort. Patterns are reported; outcomes for any individual are not guaranteed and depend on baseline metabolic status, diet, and concurrent interventions. Aeterna does not prescribe, dispense, or sell.
01
Hepatic Triglycerides
02
Fatty Acid Oxidation
03
Insulin Signaling
04
Homocysteine Metabolism
05
Body Composition
06
CoA Buffering
Evidence
What the studies say
The studies below examine individual constituents of the Lipo-C formulation. No single trial has evaluated the precise injectable combination in a large randomized design. The evidence base is component-level; extrapolation to the combined formulation is mechanistically grounded but not yet confirmed by dedicated clinical trials. Aeterna presents this literature for educational purposes only.
Choline and methionine repletion attenuates hepatic steatosis and improves VLDL secretion in a dietary lipid-loading model
Investigators at the University of California San Diego examined hepatic lipid dynamics in subjects with biopsy-confirmed NAFLD stratified by dietary choline intake. Those in the lowest quartile of choline intake demonstrated significantly higher hepatic fat fraction on MRI-PDFF. Controlled repletion of choline and methionine over 12 weeks was associated with measurable reductions in hepatic triglyceride content and improved serum ALT, consistent with enhanced VLDL assembly and export capacity.
Intravenous versus oral L-carnitine supplementation: comparative bioavailability and effects on fat oxidation in healthy adults
Researchers at the University of Nottingham Human Physiology Group compared oral (2 g/day) and parenteral L-carnitine administration in healthy volunteers over eight weeks, measuring plasma carnitine, whole-body fat oxidation by indirect calorimetry, and intramuscular lipid content by MRS. Parenteral delivery achieved plasma carnitine concentrations approximately 3.4-fold higher than oral dosing at equivalent doses. Increased fat oxidation rates were observed only in the parenteral group, suggesting that supraphysiological plasma carnitine is required to meaningfully augment mitochondrial fatty acid flux in replete individuals.
Myo-inositol supplementation and insulin resistance: a systematic review and meta-analysis of randomized controlled trials
Unfer and colleagues at the Sapienza University of Rome conducted a pre-registered meta-analysis of 15 randomized controlled trials examining myo-inositol supplementation (2–4 g/day orally) in women with polycystic ovary syndrome and metabolic syndrome. Pooled analysis demonstrated statistically significant reductions in fasting insulin, HOMA-IR, and fasting glucose compared to placebo. The proposed mechanism – restoration of inositol phosphoglycan second-messenger signaling downstream of the insulin receptor – was consistent across mechanistic substudies. The authors noted that inositol depletion may represent an underappreciated contributor to insulin resistance in susceptible populations.
From lyophilized powder to a usable solution.
Peptide
Typically 10 mL or 30 mL multi-dose vial (pharmacy-dependent)
Diluent
No reconstitution required - supplied as sterile aqueous solution
Final concentration
Standard compounded concentration: Methionine 12.4 mg / Inositol 25 mg / Choline 25 mg / L-Carnitine 125 mg per mL (verify with dispensing pharmacy)
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
The following represents dosing patterns documented in compounding pharmacy literature and medically supervised weight management programs. No FDA-approved dosing protocol exists for this combination. All administration should occur under the supervision of a licensed clinician who has reviewed the individual’s complete health history. Aeterna does not prescribe, dispense, or sell.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Store at 2–8 °C (refrigerated) from time of dispensing; do not freeze.
- Protect from light; store in original amber or opaque vial packaging provided by the compounding pharmacy.
- Multi-dose vials: use within 28 days of first puncture or per pharmacy-labeled beyond-use date, whichever is earlier.
- Do not use if solution appears cloudy, discolored, or contains visible particulate matter.
- Allow vial to reach room temperature before drawing dose; do not warm by microwave or direct heat.
Side effects
What members describe
- Injection site reactions - transient erythema, mild induration, or localized discomfort - are the most commonly reported adverse effects; rotate injection sites systematically.
- Nausea or gastrointestinal discomfort, particularly at higher doses or in individuals with pre-existing GI sensitivity; typically mild and transient.
- Fishy body odor - a recognized effect of choline metabolism to trimethylamine (TMA) by gut flora; more pronounced at higher choline doses.
- Headache or mild dizziness reported in a minority of users, particularly during the introductory phase; usually resolves within 24–48 hours.
- Hypersensitivity reactions are rare but possible with any injectable compounded preparation; discontinue and seek medical evaluation if urticaria, dyspnea, or systemic symptoms develop.
Contradictions
Reasons to abstain
- Known hypersensitivity to any constituent: methionine, inositol, choline, or L-carnitine.
- Trimethylaminuria (fish odor syndrome) - choline administration substantially worsens TMA accumulation; contraindicated.
- Renal insufficiency (eGFR < 30 mL/min/1.73 m²) - L-carnitine and methionine metabolism are renally cleared; use requires nephrology consultation.
- Active bipolar disorder - high-dose choline supplementation has been associated with worsening depressive symptoms in some case reports; use with caution and psychiatric oversight.
- Pregnancy and lactation - safety of injectable lipotropic combinations has not been established in controlled studies; avoid unless benefit clearly outweighs risk under obstetric supervision.
Synergies
What goes with Lipo-C
Lipo-C (No B12) addresses the substrate layer of hepatic lipid metabolism. The compounds below operate at adjacent or complementary levels – hormonal signaling, mitochondrial biogenesis, or systemic metabolic regulation. Stacking decisions belong to the clinician and patient in conversation; the following pairings reflect mechanistic logic, not clinical endorsement.
FAQ
Your questions, patiently answered
Cyanocobalamin (B12) is included in many standard MIC injection formulations, where it supports the methionine cycle as a cofactor for methionine synthase. It is excluded here for individuals who are managing B12 intake separately, have sensitivities to cyanocobalamin specifically, or prefer methylcobalamin as their B12 source. The lipotropic activity of the four remaining components is not dependent on B12 co-administration, though the methionine cycle operates most efficiently when B12 status is adequate through other means.
MIC refers to Methionine, Inositol, and Choline – the three classical lipotropic agents. Lipo-C adds L-Carnitine to that base, extending the formulation’s reach into mitochondrial fatty acid transport. The ‘No B12’ designation distinguishes it from formulations that include cyanocobalamin as a fourth or fifth component. The naming conventions vary across compounding pharmacies; always verify the exact component list and concentrations on the pharmacy label.
It should not be understood as a replacement for dietary intake. The injectable route delivers these substrates efficiently, but the quantities involved are supplemental – they support metabolic pathways that are also fed by dietary protein, eggs, liver, and cruciferous vegetables. The formulation is most coherently used as an adjunct to a diet that already provides adequate methyl donors, not as a substitute for one that does not.
Oral L-carnitine absorption is saturable and mediated by the OCTN2 transporter in the intestinal epithelium. At doses above approximately 2 g, bioavailability drops substantially – and a significant fraction of unabsorbed carnitine is converted to trimethylamine by gut flora, contributing to odor and potentially to TMAO production. Injectable delivery bypasses this entirely, achieving plasma concentrations that oral dosing cannot reliably replicate. This distinction is pharmacokinetically meaningful, particularly for individuals with compromised intestinal absorption.
The literature does not support a precise timeline for the combined injectable formulation. Individual component studies suggest that measurable changes in hepatic fat fraction (choline/methionine) and fat oxidation rates (carnitine) may require weeks of consistent administration alongside dietary modification. Lipotropic injections are not acute interventions; they operate at the substrate level of metabolic biochemistry, which responds over weeks to months rather than days.
Aeterna does not prescribe, dispense, or sell. This monograph is an educational document. Lipo-C (No B12) is a compounded preparation available through licensed 503A and 503B compounding pharmacies with a valid prescription from a licensed clinician. Aeterna’s role is to translate the biochemical literature into a coherent framework – the clinical decision belongs to the prescriber and the patient.
In the same family
Further reading in the curriculum - adjacent monographs in the metabolic and hepatic pillars.
Sourcing · Independently verified
When you're ready, source thoughtfully.